Literature DB >> 21357713

Mutant BCR-ABL clones in chronic myeloid leukemia.

Michael S Mathisen, Hagop M Kantarjian, Jorge Cortes, Elias Jabbour.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21357713      PMCID： PMC3046262          DOI： 10.3324/haematol.2010.039560

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Hagop Kantarjian; Neil P Shah; Andreas Hochhaus; Jorge Cortes; Sandip Shah; Manuel Ayala; Beatriz Moiraghi; Zhixiang Shen; Jiri Mayer; Ricardo Pasquini; Hirohisa Nakamae; Françoise Huguet; Concepción Boqué; Charles Chuah; Eric Bleickardt; M Brigid Bradley-Garelik; Chao Zhu; Ted Szatrowski; David Shapiro; Michele Baccarani
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

Review 2.  Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.

Authors:  Elias Jabbour; Susan Branford; Giuseppe Saglio; Dan Jones; Jorge E Cortes; Hagop M Kantarjian
Journal:  Cancer       Date:  2010-11-29       Impact factor: 6.860

3.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Authors:  Brian J Druker; François Guilhot; Stephen G O'Brien; Insa Gathmann; Hagop Kantarjian; Norbert Gattermann; Michael W N Deininger; Richard T Silver; John M Goldman; Richard M Stone; Francisco Cervantes; Andreas Hochhaus; Bayard L Powell; Janice L Gabrilove; Philippe Rousselot; Josy Reiffers; Jan J Cornelissen; Timothy Hughes; Hermine Agis; Thomas Fischer; Gregor Verhoef; John Shepherd; Giuseppe Saglio; Alois Gratwohl; Johan L Nielsen; Jerald P Radich; Bengt Simonsson; Kerry Taylor; Michele Baccarani; Charlene So; Laurie Letvak; Richard A Larson
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

4.  High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy.

Authors:  Stephanie G Willis; Thoralf Lange; Shadmehr Demehri; Sandra Otto; Lucy Crossman; Dietger Niederwieser; Eric P Stoffregen; Shannon McWeeney; Ines Kovacs; Byung Park; Brian J Druker; Michael W Deininger
Journal:  Blood       Date:  2005-05-24       Impact factor: 22.113

5.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors:  B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

6.  Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.

Authors:  Martin C Müller; Jorge E Cortes; Dong-Wook Kim; Brian J Druker; Philipp Erben; Ricardo Pasquini; Susan Branford; Timothy P Hughes; Jerald P Radich; Lynn Ploughman; Jaydip Mukhopadhyay; Andreas Hochhaus
Journal:  Blood       Date:  2009-09-24       Impact factor: 22.113

7.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Authors:  Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

8.  Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy.

Authors:  Benjamin Hanfstein; Martin C Müller; Sebastian Kreil; Thomas Ernst; Thomas Schenk; Christian Lorentz; Uwe Schwindel; Armin Leitner; Rüdiger Hehlmann; Andreas Hochhaus
Journal:  Haematologica       Date:  2010-12-06       Impact factor: 9.941

9.  Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?

Authors:  Susan Branford; Junia V Melo; Timothy P Hughes
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

Review 10.  Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

Authors:  Michele Baccarani; Jorge Cortes; Fabrizio Pane; Dietger Niederwieser; Giuseppe Saglio; Jane Apperley; Francisco Cervantes; Michael Deininger; Alois Gratwohl; François Guilhot; Andreas Hochhaus; Mary Horowitz; Timothy Hughes; Hagop Kantarjian; Richard Larson; Jerald Radich; Bengt Simonsson; Richard T Silver; John Goldman; Rudiger Hehlmann
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544
View more
  6 in total

1.  Incidence and clinical importance of BCR-ABL1 mutations in Iranian patients with chronic myeloid leukemia on imatinib.

Authors:  Golale Rostami; Mohammad Hamid; Majid Yaran; Mohsen Khani; Morteza Karimipoor
Journal:  J Hum Genet       Date:  2015-03-05       Impact factor: 3.172

Review 2.  Potential Anticancer Properties of Osthol: A Comprehensive Mechanistic Review.

Authors:  Yalda Shokoohinia; Fataneh Jafari; Zeynab Mohammadi; Leili Bazvandi; Leila Hosseinzadeh; Nicholas Chow; Piyali Bhattacharyya; Mohammad Hosein Farzaei; Ammad Ahmad Farooqi; Seyed Mohammad Nabavi; Mükerrem Betül Yerer; Anupam Bishayee
Journal:  Nutrients       Date:  2018-01-03       Impact factor: 5.717

3.  Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem/progenitor cells in chronic myelogenous leukemia.

Authors:  Hu Lei; Han-Zhang Xu; Hui-Zhuang Shan; Meng Liu; Ying Lu; Zhi-Xiao Fang; Jin Jin; Bo Jing; Xin-Hua Xiao; Shen-Meng Gao; Feng-Hou Gao; Li Xia; Li Yang; Li-Gen Liu; Wei-Wei Wang; Chuan-Xu Liu; Yin Tong; Yun-Zhao Wu; Jun-Ke Zheng; Guo-Qiang Chen; Li Zhou; Ying-Li Wu
Journal:  Nat Commun       Date:  2021-01-04       Impact factor: 14.919

4.  FAM167A is a key molecule to induce BCR-ABL-independent TKI resistance in CML via noncanonical NF-κB signaling activation.

Authors:  Taewoo Yang; Kyu-Young Sim; Gwang-Hoon Ko; Jae-Sook Ahn; Hyeoung-Joon Kim; Sung-Gyoo Park
Journal:  J Exp Clin Cancer Res       Date:  2022-03-03

5.  The Impact of SKP2 Gene Expression in Chronic Myeloid Leukemia.

Authors:  Hossam Hodeib; Dina Abd El Hai; Mohamed A Tawfik; Alzahraa A Allam; Ahmed F Selim; Mohamed E Sarhan; Amal Selim; Nesreen M Sabry; Wael Mansour; Amira Youssef
Journal:  Genes (Basel)       Date:  2022-05-26       Impact factor: 4.141

6.  Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients.

Authors:  Marjanu Hikmah Elias; Abdul Aziz Baba; Azlan Husin; Abu Dzarr Abdullah; Rosline Hassan; Goh Ai Sim; S Fadilah Abdul Wahid; Ravindran Ankathil
Journal:  Hematol Rep       Date:  2012-11-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.